Zebrafish models for glucocorticoid-induced osteoporosis

Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis due to excessive or long-term glucocorticoid administration, disturbing the homeostasis between bone formation and bone resorption. The bone biology of zebrafish shares a high degree of similarities with mam...

Full description

Saved in:
Bibliographic Details
Published inCi ji yi xue za zhi Vol. 34; no. 4; pp. 373 - 380
Main Authors Lin, Wen-Ying, Dharini, Kameshwara, Peng, Cheng-Huan, Lin, Chung-Yen, Yeh, Kuang-Ting, Lee, Wen-Chih, Lin, Ming-Der
Format Journal Article
LanguageEnglish
Published India Wolters Kluwer - Medknow Publications 01.10.2022
Medknow Publications and Media Pvt. Ltd
Wolters Kluwer - Medknow
Wolters Kluwer Medknow Publications
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis due to excessive or long-term glucocorticoid administration, disturbing the homeostasis between bone formation and bone resorption. The bone biology of zebrafish shares a high degree of similarities with mammals. In terms of molecular level, genes and signaling pathways related to skeletogenesis are also highly correlated between zebrafish and humans. Therefore, zebrafish have been utilized to develop multiple GIOP models. Taking advantage of the transparency of zebrafish larvae, their skeletal development and bone mineralization can be readily visualized through in vivo staining without invasive experimental handlings. Moreover, the feasibility of using scales or fin rays to study bone remodeling makes adult zebrafish an ideal model for GIOP research. Here, we reviewed current zebrafish models for GIOP research, focused on the tools and methods established for examining bone homeostasis. As an in vivo, convenient, and robust model, zebrafish have an advantage in performing high-throughput drug screening and could be used to investigate the action mechanisms of therapeutic drugs.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Both authors contributed equally to this work.
ISSN:1016-3190
2223-8956
2223-8956
DOI:10.4103/tcmj.tcmj_80_22